PORTLAND, Ore. & HALIFAX, Nova Scotia--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free injection therapy (NFIT) systems, and ImmunoVaccine Technologies, Inc. (IVT), a vaccine development company, today announced they have entered into a collaborative Research Agreement to assess utilization of the Biojector® 2000 for the delivery of IVT’s unique vaccine enhancement platform, DepoVaxTM.
